Oncology
Economist Brussels Day 2

9th Annual World Cancer Series: Day 2

As Economist Impact’s World Cancer Series continues, Day Two firmly takes up focus on the patient voice, with a presentation by Eileen Page, chief executive of Innovation Advantage 2020 to

Featured Content

R&D
pharmaphorum podcast episode 98

Turning drug development on its head

Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho

Oncology
Greg Deener at CAR-TCR

CAR-TCR 2023 – Greg Deener

In late August, pharmaphorum traveled to Boston to cover CAR-TCR, a conference dedicated to the fast-moving cell therapy space.

Newsletters and Deep Dive
digital magazine

Latest News

Views & Analysis

Oncology
Economist Brussels Day 2

9th Annual World Cancer Series: Day 2

As Economist Impact’s World Cancer Series continues, Day Two firmly takes up focus on the patient voice, with a presentation by Eileen Page, chief executive of Innovation Advantage 2020 to

Deep Dive

Sales & Marketing
Celebrating 75 Years of the NHS: A timeline

Celebrating 75 Years of the NHS: A timeline

Since its inception in 1948, the National Health Service (NHS) has played a crucial role in providing accessible healthcare to millions in the United Kingdom.

White Papers & Webinar

Sales & Marketing
Coaching Never Sleeps
Sponsored

Coaching Never Sleeps

Coaching has developed into one of the most powerful tools in a fast-changing pharmaceutical sector.

Podcasts & Video

R&D
pharmaphorum podcast episode 98

Turning drug development on its head

Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho

Oncology
Greg Deener at CAR-TCR

CAR-TCR 2023 – Greg Deener

In late August, pharmaphorum traveled to Boston to cover CAR-TCR, a conference dedicated to the fast-moving cell therapy space.

Partner Content

R&D
2nd Innate Killer Europe Summit
Partner Content

2nd Innate Killer Europe Summit

The 2nd Innate Killer Europe Summit will gather 80+ key European Gamma Delta T, NK, iNKT, neutrophil, and macrophage developers in October to chase the holy grail of efficacious, off-the-sh

R&D
3rd Synthetic Biology-Based Therapeutics Summit
Partner Content

3rd Synthetic Biology-Based Therapeutics Summit

The 3rd Synthetic Biology-Based Therapeutics Summit is a platform uniting academia, engineers, and drug developers working towards increased specificity, durability and potency.